Table 4.

CD169 score and traditional prognostic markers in relation to prostate cancer death within the subgroup of patients with PSA‐relapse

	Prostate cancer death
	No (mean ± SD)	Yes (mean ± SD)		MWU test, P‐value
Pre‐operative PSA	10.6 ± 5.0	12.1 ± 6.5		0.580
Gleason score	7.1 ± 0.61	7.3 ± 0.82		0.380
	No (n)	Yes (n)	Total (n)	Fisher's exact test, P‐value
CD169 score
Low	7	7	14
High	26	3	29
Total	33	10	43	0.007
Pre‐operative PSA
≤10	20	5	25
>10	13	5	18
Total	33	10	43	0.717
PSA‐nadir
≤0.1	26	5	31
>0.1	7	5	12
Total	33	10	43	0.110
ISUP Gleason grade group
Low (ISUP 1‐2)	23	5	28
High (ISUP 3‐5)	10	5	15
Total	33	10	43	0.281
Tumor stage
pT2	7	2	9
pT3	26	8	34
Total	33	10	43	1.00
Surgical margins
Positive	19	7	26
Negative	14	3	17
Total	33	10	43	0.714

MWU = Mann‐Whitney U; SD = Standard Deviation.